Hanwha Insurers Invest In CHA Biotech

Hanwha Group’s insurance units committed 100 billion won ($67.85 million) to buy new shares in CHA Biotech on Friday, with Hanwha General Insurance investing 70 billion won and Hanwha Life Insurance 30 billion won. The insurers said they will combine insurance infrastructure with CHA’s digital-healthcare capabilities to pursue life-cycle services and mid- to long-term cooperation. The move follows a 10 billion won LG CNS investment announced a day earlier.